Patrys Limited announced new pre-clinical animal data for its lead candidate, PAT-DX1. Results of the study provide further support that PAT-DX1 could suppress tumor growth in patients with triple-negative breast cancer brain metastases. The study employed a relatively short dosing regime, where PAT-DX1 was administered for just one weekly cycle of 3 doses relative to the precursor study with four weekly cycles. Results of the study showed that even with the reduced and shortened dosing regimen, PAT-DX1 was able to significantly suppress TNBC brain metastases after just one week of treatment, with responses maintained for several weeks after the drug administration was discontinued. A combination of both PAT-DX1 and low dose radiation therapy resulted in significantly increased tumor suppression. No toxicity associated with PAT-DX1 treatment was observed. The new study forms part of the Company’s broader program to identify and optimize dosing regimens for future studies. Patrys and the Yale School of Medicine are now planning additional studies to explore the interactions between different radiation and PAT-DX1 dosing regimens that will inform and guide the clinical development of PAT-DX1.